Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Committed to advancing new medicines to benefit patients with viral-associated cancers and other serious diseases.

Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Recent News

April 11, 2018

Viracta Initiates Treatment of First Patient in EBV+ Lymphoma Clinical Trial with Tractinostat - San Diego, CA, April 11, 2018 - Viracta Therapeutics, a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, has initiated treatment of the first patient in a Phase 1b/2 clinical trial in Epstein-Barr virus-positive (EBV+) lymphomas. The Company’s unique therapeutic approach is the first targeted, orally administered therapy for EBV+ lymphomas. Read More

Events

July 29, 2018

Rob McRae, Viracta’s head of R&D Operations, will attend the International Conference on EBV & KSHV in Madison, WI. The Viracta presentation on July 29, 2018 is entitled, “Dual Role in Fighting Viral Malignancies: Next Generation Epigenetic Modifier for Viral Gene Activation and Anti-Tumor Immune Response.” Read More

Recent News

April 11, 2018

Viracta Initiates Treatment of First Patient in EBV+ Lymphoma Clinical Trial with Tractinostat - San Diego, CA, April 11, 2018 - Viracta Therapeutics, a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, has initiated treatment of the first patient in a Phase 1b/2 clinical trial in Epstein-Barr virus-positive (EBV+) lymphomas. The Company’s unique therapeutic approach is the first targeted, orally administered therapy for EBV+ lymphomas. Read More

Events

July 29, 2018

Rob McRae, Viracta’s head of R&D Operations, will attend the International Conference on EBV & KSHV in Madison, WI. The Viracta presentation on July 29, 2018 is entitled, “Dual Role in Fighting Viral Malignancies: Next Generation Epigenetic Modifier for Viral Gene Activation and Anti-Tumor Immune Response.” Read More